---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-012288"
form_type: "8-K"
ticker: null
cik: "0001537561"
company_name: "Arch Therapeutics, Inc."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T14:04:44.100501+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Arch Therapeutics files Chapter 11, expects no shareholder recovery; stalking horse bid from Vivex Biologics

## Summary
- Filed Chapter 11 on April 18, 2025; stalking horse bid by Vivex Biologics for substantially all assets.
- Court approved bidding procedures; sale hearing set for June 20, 2025. DIP credit bid up to $900K.
- Prepetition secured parties to receive $500K carve-out; anticipated no recovery for shareholders.
- Auditor Weinberg resigned May 22, 2025; company non-compliant with SEC filings since Sep 2024 10-K.
- Securities moved to OTC Expert Market (ARTHQ); board reduced to two members, single officer.

## SEC filing metadata
- accession: 0001641172-25-012288
- form_type: 8-K
- cik: 0001537561
- company_name: Arch Therapeutics, Inc.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.03, 2.04, 3.01, 4.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1537561/000164117225012288/0001641172-25-012288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1537561/000164117225012288/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-012288
- JSON: https://secwatch.observer/filing/0001641172-25-012288.json
- Plain text: https://secwatch.observer/filing/0001641172-25-012288.txt

## Key facts
- Auditor Changes
  Weinberg & Company, P.A. resigned as auditor of Arch Therapeutics, Inc..
  - Action: resignation
  - Auditor: Weinberg & Company, P.A.
  source text: On May 22, 2025, Weinberg & Company, P.A. (“Weinberg”) notified the Company of its resignation as the independent registered public accounting firm for the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1537561/000164117225012288/0001641172-25-012288-index.htm
- Distress & Bankruptcy
  Arch Therapeutics, Inc. entered chapter 11 in United States Bankruptcy Court, District of Massachusetts (Worcester) (petition 2025-04-18).
  - Proceeding: chapter 11
  - Court: United States Bankruptcy Court, District of Massachusetts (Worcester)
  - Petition: 2025-04-18
  source text: On April 18, 2025, Arch Therapeutics, Inc. (the "Company" or "Arch Therapeutics, Inc.") and its fully owned subsidiary, Arch Biosurgery, Inc., filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court, District of Massachusetts (Worcester) (the "Court"), case 25-40409.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1537561/000164117225012288/0001641172-25-012288-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.